Friday, 21 Feb 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
07 Nov 2017 Social RT @japaoli19: Benefits of IL6 blockade on insulin resistance in RA #1400 #ACR17 @RheumNow https://t.co/tYFYRnRlof
13 Apr 2017 Social Patient survey on BIOSIMILARs. Vote here if you have #RA, #PsA, #PSO, #AS, #IBD >> https://t.co/EfNSZNhhxz
12 Jun 2018 Social Humira patent life in EU ends ~Oct 2018; and thus many strange biosimilar names from Amgen (Amgevita, Solymbi), Boehringer Ingelheim (Cyltezo), Samsung (Imraldi) & soon Sandoz (Halimatoz, Hefiya, Hyrimoz) https://t.co/3oDdRnt0Bj
19 Aug 2019 Social Abbvie has announced that the annual price for its new FDA approved JAK1 inhibitor, Rinvoq, will be $59,000. https://t.co/22LIetdTUh
04 May 2017 Social Pfizer submitted tofacitinib NDA to FDA for psoriatic arthritis. FDA prev denied the NDA for psoriasis w/ CR letter. https://t.co/bDmnc8QF3c
09 Sep 2015 Social Despite evidence of efficacy, NICE has denied biologic DMARDs to UK RA pts with moderately active disease http://t.co/1BAfVxrN6L
25 Jun 2018 Social Uncontrolled, off-label reports of Tofacitinib 10 mg bid in patients with refractory dermatomyositis - promising but more clinical trial data needed! https://t.co/vCgC0scAa9
16 Feb 2019 Social Dr Mark Genovese on Filgotinib (jak 1 inhibitor in development) showing no diff in responses despite falling 1, 2, 3 biologics #RWCS2019 https://t.co/dk7orkumEd
11 Nov 2019 Social RT @EBRheum: So much JAKi right now - RA, PsA, SLE, and more! Last tweet of the day. Curious to hear... Which JAKi do you think will win…
18 Jul 2016 Social Samsung Bioepis has filed its application for its Humira biosimilar with the European Medicines Agency https://t.co/bcfaJA2eTN
28 Aug 2017 Social Severe (ocular) Behcets study: ~half respond to TNF inhib but only half these stay in remission w/ TNFi withdrawal https://t.co/a2oGZADlle
14 Sep 2016 Social TNFi induced Psoriasis can be treated w/ TNFi D/C, another TNFi (48-85% recurrence) or Stelara. Good short review https://t.co/PAtJOOfFIV
13 Feb 2016 Social Biosimilars have changed FDA from the arbiter of drug safety/efficacy to a partner shepherding biosimilars to market https://t.co/G6NvuziaOk
29 Apr 2019 Social FDA has approved Samsung-Bioepsis biosimilar version of etanercept - Eticovo (etanercept-ykro), approved in other countries under names Benepali and Brenzys. Approval based on 596 RA pt trial w/ 52 wk ACR20 of 80.8% and 81.5% (Enbrel arm) https://t.co/r3q9dQ0Bdb
18 Oct 2017 Social Janssen halts anti-IL6 sirukumab development citing FDA rejection and need for more clinical data. https://t.co/3SLehEbLO0
02 Jun 2015 Social FDA Guidance: #Biosimilars need fingerprint-like analytics w/ reference drug & ACR20 efficacy falling betw goalposts http://t.co/F5qJcz9Mdh
22 Oct 2016 Social SURPRISE study 223 RA MTX-IR pts Rx w/ TCZ+MTX or TCZ- earlier DAS28 Resp & less Xray damage w/ addon vs switch Rx. https://t.co/HCsbfjdqtH
05 Apr 2016 Social RT @WIRheum: FDA approves Inflectra, a biosimilar to Remicade https://t.co/ypSrHrVzKP
13 Oct 2018 Social Clinical Trials Benchmark for Biosimilar Development is one of several educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi
15 Jul 2019 Social Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19.0%. Steroid sparing variable, high infx rates. https://t.co/Ff9KULlKVD